Handelsbanken Fonder AB Acquires 1,800 Shares of Guardant Health, Inc. (NASDAQ:GH)

Handelsbanken Fonder AB lifted its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 6.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,941 shares of the company’s stock after buying an additional 1,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Guardant Health were worth $884,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. R Squared Ltd purchased a new position in shares of Guardant Health in the fourth quarter worth about $26,000. JNBA Financial Advisors acquired a new stake in Guardant Health in the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in Guardant Health in the third quarter valued at approximately $34,000. Van ECK Associates Corp grew its holdings in Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock valued at $88,000 after purchasing an additional 929 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Guardant Health by 168.1% in the third quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company’s stock valued at $79,000 after purchasing an additional 2,153 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of Guardant Health stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company’s stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 2,768 shares of company stock worth $98,798 over the last quarter. 5.50% of the stock is currently owned by company insiders.

Guardant Health Stock Up 1.0 %

NASDAQ:GH opened at $42.55 on Friday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The company has a market capitalization of $5.25 billion, a P/E ratio of -11.95 and a beta of 1.32. The stock’s fifty day moving average is $40.87 and its two-hundred day moving average is $31.89.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to analysts’ expectations of $192.50 million. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on GH. JPMorgan Chase & Co. raised their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group raised their price objective on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a report on Monday, February 24th. The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Scotiabank raised their target price on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Finally, Piper Sandler raised their target price on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Nineteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus target price of $48.21.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.